LY2409881

Cat. No.: HY-B0788: FAQs
Data Sheet SDS Handling Instructions

Molarity Calculator

LY2409881 is a selective IκB kinase β (IKK2) inhibitor with an IC₅₀ of 30 nM.

For research use only. We do not sell to patients.

LY2409881 Chemical Structure

CAS No. : 946518-61-2

Size	Price	Stock
5 mg	USD 132	Ask For Quote & Lead Time
10 mg	USD 216	Ask For Quote & Lead Time
50 mg	USD 780	Ask For Quote & Lead Time
100 mg	USD 1092	Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of LY2409881:

Other Forms of LY2409881:

LY2409881 trihydrochloride In-stock

2 Publications Citing Use of MCE LY2409881

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All IKK Isoform Specific Products:

View All Isoforms

IKK-α IKK-β IKK IKKε TBK1

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

LY2409881 is a selective IκB kinase β (IKK2) inhibitor with an IC₅₀ of 30 nM.

IC₅₀ & Target^[1]

IKK2

30 nM (IC₅₀)

In Vitro

LY2409881 is an IKK2 inhibitor that inhibits TNFα-induced activation of NF-κB. By in vitro kinase assay, LY2409881 potently inhibits IKK2, with an IC₅₀ of 30 nM. In contrast, the IC₅₀ for IKK1 and other common kinases is at least one log higher. The specificity of LY2409881 for NF-κB signaling is further studied in a cell-based assay, by examining the effect of LY2409881 in the TNFα-dependent antiapoptosis function. TNFα is a well-characterized upstream stimulus of NF-κB. In the ovarian cancer cell line SKOV3, LY2409881 demonstrates moderate cytotoxicity, whereas TNFα at 10 ng/mL does not cause any cytotoxicity. In contrast, coadministration of LY2409881 and TNFα results in markedly higher cell killing compared with LY2409881. This is because TNFα-dependent activation of antiapoptotic signals mediated by NF-κB is blocked by LY2409881, while the proapoptotic TNF receptor-associated death domain (TRADD) and FAS-associated death domain (FADD) cascade pathways activated by TNFα are not affected by LY2409881^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

A well-established xenograft model of DLBCL is used to confirm the activity of LY2409881 in vivo. SCID-beige mice implanted with LY10 cell-derived tumors are given intraperitoneal injections of LY2409881 twice weekly at three different doses: 50, 100, and 200 mg/kg. The treatments are well tolerated, resulting in no death or severe morbidity of the mice. The average tumor volume is graphed as a function of time for each treatment group. The rates of tumor volume growth of the treatment groups are all significantly slower than the untreated control group (P≤0.01)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

485.04

Formula

C₂₄H₂₉ClN₆OS

CAS No.

946518-61-2

SMILES

O=C(C1=C(C=C(C2=NC(NCCCN3CCN(C)CC3)=NC=C2Cl)S4)C4=CC=C1)NC5CC5

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

In Vitro:

DMSO : ≥ 37 mg/mL (76.28 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0617 mL	10.3084 mL	20.6169 mL
5 mM	0.4123 mL	2.0617 mL	4.1234 mL
10 mM	0.2062 mL	1.0308 mL	2.0617 mL

View the Complete Stock Solution Preparation Table

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Data Sheet (278 KB) SDS (120 KB) Handling Instructions (2659 KB)

References

[1]. Deng C, et al. The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB. Clin Cancer Res. 2015 Jan 1;21(1):134-45. [Content Brief]

Cell Assay ^[1]	OCI-Ly1, OCI-Ly7, and Su-DHL4 are GCB DLBCL cell lines; OCI-Ly3, OCI-Ly10, HBL1, and Su-DHL2 are ABC DLBCL lines. These cell lines are grown in Iscove Modified Dulbecco Medium with 10% FCS. Fresh medium is added every 2 to 3 days, and the cells are kept at a cell concentration of 0.1 to 1×10⁶/mL. Cytotoxicity is evaluated using the CellTiter-Glo Reagent. Experiments are carried out in 96-well plates, with each treatment in triplicate. Samples are taken at typically 24, 48, and 72 hours after treatment. Cytotoxicity is expressed by the decreasing percentage of live cells in each treatment (LY2409881; 0.01, 0.1, 1 and 10 μM) relative to the untreated control from the same experiment, as a function of time. IC₅₀ for each cell line is calculated using the CalcuSyn Version 2.0 software^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice^[1] Mouse experiments are carried out. Five- to 7-week-old SCID beige mice are injected with 107 Ly10 cells mixed in Matrigel in the posterior flank subcutaneously. When the tumors approach 150 mm³, the mice are divided into four groups of 8 mice: (i) control group, which receive 5% dextrose in water; (ii) LY2409881 at 50 mg/kg in D5W; (iii) LY2409881 at 100 mg/kg in D5W; and (iv) LY2409881 at 200 mg/kg in D5W. LY2409881 or D5W is administered intraperitoneally on day 1 and 4 of every week for 4 weeks. The data are expressed as average tumor volume (mm3) per group as a function of time. Tumor volume is calculated. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Deng C, et al. The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB. Clin Cancer Res. 2015 Jan 1;21(1):134-45. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.0617 mL	10.3084 mL	20.6169 mL	51.5421 mL
	5 mM	0.4123 mL	2.0617 mL	4.1234 mL	10.3084 mL
	10 mM	0.2062 mL	1.0308 mL	2.0617 mL	5.1542 mL
	15 mM	0.1374 mL	0.6872 mL	1.3745 mL	3.4361 mL
	20 mM	0.1031 mL	0.5154 mL	1.0308 mL	2.5771 mL
	25 mM	0.0825 mL	0.4123 mL	0.8247 mL	2.0617 mL
	30 mM	0.0687 mL	0.3436 mL	0.6872 mL	1.7181 mL
	40 mM	0.0515 mL	0.2577 mL	0.5154 mL	1.2886 mL
	50 mM	0.0412 mL	0.2062 mL	0.4123 mL	1.0308 mL
	60 mM	0.0344 mL	0.1718 mL	0.3436 mL	0.8590 mL

LY2409881 Related Classifications

NF-κB
IKK

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

LY2409881946518-61-2LY 2409881LY-2409881IKKIκB kinaseI kappa B kinaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks